Lightlake to begin opioid antagonist derived nasal spray Phase II trials in Binge Eating Disorder

Aug 25 2011

Lightlake Therapeutics Inc. (OTCBB: LLTP) ("Lightlake" or "the "Company"), an early stage biopharmaceutical company currently developing a nasal spray for the treatment of overweight and obese patients with Binge Eating Disorder, today announced that its patient testing stage of the Phase II clinical trials will start August 26th, 2011

Dr. Roger Crystal, CEO of Lightlake commented, "We are excited to commence the definitive stage of testing of a product that we believe will be a solution to a disease thought to affect a significant proportion of obese and overweight patients today. We recently completed stability testing in an effort to ensure that our nasal spray adheres to internationally recognised safety standards in delivering an effective treatment. Moreover, we have an excellent control group in place, as we were able to select 138 patients from over 900 applicants wanting to participate in our trials in Helsinki. Dr. David Sinclair, our Chief Scientific Officer, revolutionized the way we treat alcoholism and drug addiction through his research into opioid antagonists, and we are confident that in working with him, we can develop an opioid antagonist derived nasal spray for the treatment of those with Binge Eating Disorder."

In addition to treating patients with Binge Eating Disorder, Lightlake believes its nasal spray could also beneficial for those with bingeing behaviour, which is thought to exist in one third of obese patients. The Company projects that its Phase II trials will be completed early next year and if successful, Lightlake plans to conduct its Phase III at Imperial College London and other international institutions. The Company will work with Celesio AG to develop a pharmacist delivered treatment program, and intends to establish similar commercial relationships over the next 12 months.

Source: Lightlake Therapeutics Inc.